Physician profile
Kelly E Kries
NPI 1346275583
$1,998.87
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $263 · 2021: $494 · 2022: $314 · 2023: $489 · 2024: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $600.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $393.60 | 2019-2023 | Bexsero, Pediarix, Shingrix |
| Ironshore Pharmaceuticals INC. | $184.95 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $150.88 | 2021-2023 | Qelbree |
| Corium, LLC | $147.92 | 2021-2023 | Azstarys |
| Pfizer INC. | $135.04 | 2019-2023 | |
| Sanofi Pasteur INC. | $132.38 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $113.36 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.25 | 2020-2021 | |
| Abbvie INC. | $75.10 | 2019-2024 | |
| Novo Nordisk INC | $72.47 | 2019-2023 | Wegovy |
| Ultragenyx Pharmaceutical INC. | $52.89 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $49.52 | 2024 | |
| Merck Sharp & Dohme LLC | $48.59 | 2019-2021 | |
| Cranial Technologies, INC | $41.22 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $40.32 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $29.02 | 2021 | |
| Lilly USA, LLC | $28.95 | 2023 | Mounjaro, Trulicity |
| Kyowa Kirin, INC. | $27.51 | 2023 | Crysvita |
| Sobi, INC | $21.12 | 2021 | |
| Abbott Laboratories | $19.25 | 2022 | |
| Seqirus USA INC | $17.37 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Tris Pharma INC | $15.96 | 2021 | |
| Ironwood Pharmaceuticals, INC | $15.55 | 2023 | Linzess |
| Paratek Pharmaceuticals, INC. | $14.38 | 2024 | Nuzyra |
| Kaleo, INC. | $13.56 | 2020 | |
| Alfasigma USA, INC. | $13.53 | 2021 | |
| Amgen INC. | $13.49 | 2023 | Repatha |
| Shire North American Group INC | $12.79 | 2019 | |
| Medtronic, INC. | $12.64 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Kries listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.